Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

Managing the Condition: Standard of Care Treatment Options

At a Glance

Standard treatments for HCM aim to reduce symptoms and protect heart function. Options range from daily medications like beta-blockers and myosin inhibitors to surgical procedures like septal myectomy or alcohol ablation. Care should be managed by an HCM Center of Excellence.

The primary goal of treatment for Hypertrophic Cardiomyopathy (HCM) is to improve your quality of life by reducing symptoms like shortness of breath and chest pain [1]. While no current treatment “cures” HCM by removing the underlying genetic mutation, modern therapies are highly effective at managing the condition and protecting your heart function [2][3].

Step 1: First-Line Medications

For most patients, treatment begins with medications designed to slow the heart rate and help the heart muscle relax [4].

  • Beta-Blockers: These are typically the first choice. They slow your heart rate, allowing the stiff heart more time to fill with blood and reducing the force of contraction to lessen obstruction [4]. Note: Beta-blockers commonly cause significant fatigue and exercise intolerance. Many patients confuse these medication side effects with worsening HCM symptoms. Always communicate with your doctor if you feel worse after starting them [5].
  • Calcium Channel Blockers (e.g., Verapamil): If you cannot take beta-blockers, these medications offer a similar benefit by helping the heart muscle relax [4].
  • Disopyramide: This is an older medication sometimes added to beta-blockers to further reduce the force of the heart’s contraction in obstructive cases [4].

Step 2: Advanced Medical Therapy (Myosin Inhibitors)

If first-line medications do not provide enough relief, a newer class of drugs called Cardiac Myosin Inhibitors (such as mavacamten) may be an option for obstructive HCM [6][7].

  • How they work: These drugs target the “molecular engines” (myosin) of the heart directly, preventing them from pulling too hard. This reduces the thickening of the muscle and the obstruction in the heart [8][9].
  • Critical Safety Warnings: Mavacamten carries a black box warning because it can overly weaken the heart muscle, leading to heart failure (reduced ejection fraction). It also has severe, potentially dangerous drug-drug interactions with common medications (CYP450 inhibitors) [6][10]. You must always consult your pharmacist or doctor before starting any new medication or supplement. It is also strictly contraindicated during pregnancy [11].
  • Monitoring (REMS): Because of these risks, you will be enrolled in a mandatory monitoring program (REMS) and require regular echocardiograms to ensure your heart is pumping safely [10][11].

Step 3: Septal Reduction Therapy (SRT)

For patients with obstructive HCM who still have severe, lifestyle-limiting symptoms despite taking medications, invasive options may be considered. These are generally recommended when the pressure gradient in the heart’s outflow tract is 50 mmHg or higher [2][12].

Surgical Septal Myectomy

In this open-heart procedure, a surgeon removes a small amount of the thickened heart muscle to clear the path for blood flow [13][14].

  • Pros: It is the “gold standard” for relief and can also fix other issues, like a leaky mitral valve, at the same time [15][16].
  • Cons: It is a major surgery requiring a hospital stay and several weeks of recovery [2].

Alcohol Septal Ablation (ASA)

This is a less invasive procedure performed in a cardiac catheterization lab. A doctor injects a small amount of pure alcohol into a specific artery to cause a controlled, “tiny heart attack” in the thickened muscle, causing it to thin out over time [17][18].

  • Pros: No large incision and a much shorter recovery time than surgery [17].
  • Cons: There is a significant and notable risk (historically 10-20% depending on the center) of causing a complete heart block, which requires the implantation of a permanent pacemaker [18][19]. It may also not be suitable for all types of heart anatomy.

Choosing Your Path

Deciding between continuing medications, starting a myosin inhibitor, or pursuing a procedure is a complex choice. Current guidelines emphasize that this decision should be made through shared decision-making between you and a multidisciplinary team at a dedicated HCM Center of Excellence [2][20][21]. These centers have the highest success rates because they perform these procedures frequently [20].

Return to Home

Common questions in this guide

What are the first-line medications for HCM?
Treatment typically begins with medications like beta-blockers or calcium channel blockers. These drugs slow the heart rate and help the stiff heart muscle relax, allowing it more time to fill with blood and reducing the force of contraction.
How does mavacamten work for hypertrophic cardiomyopathy?
Mavacamten is a cardiac myosin inhibitor that targets the heart's molecular engines directly to stop them from pulling too hard. This process reduces the thickening of the heart muscle and relieves blood flow obstruction.
Are there serious side effects of taking cardiac myosin inhibitors?
Mavacamten carries a risk of overly weakening the heart muscle, which can lead to heart failure. Because of this, patients must enroll in a mandatory monitoring program and receive regular echocardiograms to ensure their heart is pumping safely.
What is the difference between a septal myectomy and an alcohol septal ablation?
Septal myectomy is an open-heart surgery where a portion of the thickened heart muscle is physically removed. Alcohol septal ablation is a less invasive catheter procedure that uses a small amount of alcohol to shrink the thickened muscle over time.
Why is it important to go to an HCM Center of Excellence for treatment?
Specialized centers have a multidisciplinary team of experts who perform HCM procedures frequently. Guidelines emphasize that complex treatment decisions should be made through shared decision-making at these high-volume centers to ensure the highest success rates.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently on the 'maximally tolerated' dose of my first-line medications, or is there room to increase them?
  2. 2.Based on my symptoms and imaging, would you recommend adding a cardiac myosin inhibitor like mavacamten or moving toward septal reduction therapy?
  3. 3.If we choose mavacamten, what is the process for the mandatory REMS monitoring and how often will I need echocardiograms?
  4. 4.If I need septal reduction therapy, which procedure (myectomy or ablation) is a better fit for my specific heart anatomy?
  5. 5.Does this hospital meet the 'high-volume center' standards for myectomy, or should I seek a referral to an HCM Center of Excellence?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures.

    Banthiya S, Check L, Atkins J

    US cardiology 2024; (18()):e17 doi:10.15420/usc.2023.21.

    PMID: 39508003
  2. 2

    2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.

    Ommen SR, Ho CY, Asif IM, et al.

    Circulation 2024; (149(23)):e1239-e1311 doi:10.1161/CIR.0000000000001250.

    PMID: 38718139
  3. 3

    Frequency of misdiagnosis in hypertrophic cardiomyopathy.

    Nielsen SK, Rasmussen TB, Hey TM, et al.

    European heart journal. Quality of care & clinical outcomes 2025; (11(2)):105-112 doi:10.1093/ehjqcco/qcae031.

    PMID: 38664062
  4. 4

    Through Thick and Thin: What Are the Septal Thickness Limits for Alcohol Septal Ablation?

    Fifer MA

    Circulation. Cardiovascular interventions 2016; (9(3)):e003588.

    PMID: 26884613
  5. 5

    Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond.

    Gaballa A, Jadam S, Desai MY

    Expert opinion on pharmacotherapy 2024; (25(7)):915-924 doi:10.1080/14656566.2024.2362902.

    PMID: 38813944
  6. 6

    Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy.

    Massera D, Adlestein E, Frejat S, et al.

    Journal of the American Heart Association 2025; (14(15)):e041565 doi:10.1161/JAHA.125.041565.

    PMID: 40673527
  7. 7

    The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review.

    Othman L, Koskina L, Huerta N, Rao SJ

    Heart failure reviews 2025; (30(2)):453-467 doi:10.1007/s10741-024-10476-w.

    PMID: 39690360
  8. 8

    Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives.

    Ramadan MM, Al-Najjar RA, Abady RS, et al.

    Cureus 2025; (17(4)):e82722 doi:10.7759/cureus.82722.

    PMID: 40400802
  9. 9

    Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

    Spertus JA, Fine JT, Elliott P, et al.

    Lancet (London, England) 2021; (397(10293)):2467-2475 doi:10.1016/S0140-6736(21)00763-7.

    PMID: 34004177
  10. 10

    Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program.

    Desai MY, Seto D, Cheung M, et al.

    Circulation. Heart failure 2025; (18(1)):e012441 doi:10.1161/CIRCHEARTFAILURE.124.012441.

    PMID: 39523955
  11. 11

    Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response.

    Owens AT, Desai M, Wheeler MT, et al.

    Journal of the American Heart Association 2024; (13(17)):e033767 doi:10.1161/JAHA.124.033767.

    PMID: 39206723
  12. 12

    Alcohol septal ablation: A useful tool in our arsenal against hypertrophic obstructive cardiomyopathy.

    Savarimuthu S, Harky A

    Journal of cardiac surgery 2020; (35(8)):2017-2024 doi:10.1111/jocs.14815.

    PMID: 32652778
  13. 13

    Randomized Controlled Trial of Moderate- and High-Intensity Exercise Training in Patients With Hypertrophic Cardiomyopathy: Effects on Fitness and Cardiovascular Response to Exercise.

    MacNamara JP, Dias KA, Hearon CM, et al.

    Journal of the American Heart Association 2023; (12(20)):e031399 doi:10.1161/JAHA.123.031399.

    PMID: 37830338
  14. 14

    Interventions in Hypertrophic Obstructive Cardiomyopathy.

    Ding WY, Meah MN, Stables R, Cooper RM

    The Canadian journal of cardiology 2024; (40(5)):833-842 doi:10.1016/j.cjca.2023.12.001.

    PMID: 38070769
  15. 15

    Septal reduction therapies for obstructive hypertrophic cardiomyopathy: Current strategies and evolving innovations.

    Cui H, Lai Y, Schaff HV

    Trends in cardiovascular medicine 2026; doi:10.1016/j.tcm.2026.02.004.

    PMID: 41654203
  16. 16

    Tailored Planning of Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy.

    Koo HJ, Lee SA, Jung SH, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2024; (44(1)):e230050 doi:10.1148/rg.230050.

    PMID: 38060425
  17. 17

    Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis.

    Osman M, Kheiri B, Osman K, et al.

    Clinical cardiology 2019; (42(1)):190-197 doi:10.1002/clc.23113.

    PMID: 30421437
  18. 18

    Septal Myectomy or Alcohol Ablation for Hypertrophic Cardiomyopathy: A Nationwide Inpatient Sample (NIS) Database Analysis.

    Ullah W, Warner E, Khandait H, et al.

    Cardiovascular revascularization medicine : including molecular interventions 2023; (50()):54-58 doi:10.1016/j.carrev.2023.01.013.

    PMID: 36737383
  19. 19

    A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy.

    Liebregts M, Vriesendorp PA, Mahmoodi BK, et al.

    JACC. Heart failure 2015; (3(11)):896-905.

    PMID: 26454847
  20. 20

    Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy.

    Patel N, Shetty NS, Gaonkar M, et al.

    Journal of the American Heart Association 2024; (13(21)):e036387 doi:10.1161/JAHA.124.036387.

    PMID: 39450721
  21. 21

    The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system.

    Fitzgerald P, Kusumoto F

    Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2018; (52(3)):403-408 doi:10.1007/s10840-018-0433-0.

    PMID: 30097789

This page is for informational purposes only and does not replace professional medical advice. Always consult your cardiologist or healthcare provider about your specific treatment plan and options.

Get notified when new evidence is published on Hypertrophic Cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.